Barclays PLC Grows Stock Position in Zentalis Pharmaceuticals, Inc ...

Jan 6, 2025 · Zentalis Pharmaceuticals Trading Up 8.0 %. Shares of Zentalis Pharmaceuticals stock opened at $3.24 on Monday. The firm has a market cap of $230.90 million, a P/E ratio of …

$3.24
OFF

Barclays PLC Grows Stock Position In Zentalis Pharmaceuticals, Inc ...

2 weeks from now

Jan 6, 2025 · Zentalis Pharmaceuticals Trading Up 8.0 %. Shares of Zentalis Pharmaceuticals stock opened at $3.24 on Monday. The firm has a market cap of $230.90 million, a P/E ratio of …

etfdailynews.com

5%
OFF

Barclays PLC Buys 11,748 Shares Of Zentalis Pharmaceuticals, Inc ...

2 weeks from now

Jan 6, 2025 · Barclays PLC grew its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) by 18.5% during the 3rd quarter, according to its most recent …

defenseworld.net

5%
OFF

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $10.00 …

2 weeks from now

Dec 27, 2024 · Barclays PLC grew its holdings in Zentalis Pharmaceuticals by 18.5% during the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 …

americanbankingnews.com

5%
OFF

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given ... - Defense …

2 weeks from now

Nov 29, 2024 · Barclays PLC boosted its holdings in Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at …

defenseworld.net

$10.00
OFF

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $10.00 …

2 weeks from now

Dec 2, 2024 · NASDAQ ZNTL opened at $3.61 on Friday. The stock has a 50-day simple moving average of $3.36 and a 200 day simple moving average of $4.82. Zentalis Pharmaceuticals …

etfdailynews.com

20%
OFF

Zentalis Pharmaceuticals, Inc. (ZNTL) Upgraded To Buy: Here's

2 weeks from now

Aug 26, 2022 · The upgrade of Zentalis Pharmaceuticals, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock …

nasdaq.com

$271000
OFF

Barclays PLC Purchases 15,957 Shares Of FVCBankcorp, Inc.

2 weeks from now

Jan 6, 2025 · Barclays PLC Grows Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Barclays PLC Has $271,000 Position in Organogenesis Holdings Inc. …

etfdailynews.com

9%
OFF

Barclays PLC Boosts Holdings In Tarsus Pharmaceuticals, Inc.

2 weeks from now

Dec 24, 2024 · Barclays PLC lifted its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 345.9% during the third quarter, according to the company in its most recent …

marketbeat.com

$271000
OFF

Barclays PLC Increases Stock Position In Seven Hills Realty Trust ...

2 weeks from now

Jan 6, 2025 · Barclays PLC Grows Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Barclays PLC Has $271,000 Position in Organogenesis Holdings Inc. …

etfdailynews.com

9%
OFF

Barclays PLC Grows Stock Position In Tarsus Pharmaceuticals, Inc ...

2 weeks from now

Dec 24, 2024 · Barclays PLC boosted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 345.9% during the 3rd quarter, according to the company …

defenseworld.net

$271000
OFF

Barclays PLC Increases Stock Holdings In Hooker ... - ETF Daily News

2 weeks from now

Jan 6, 2025 · Barclays PLC Grows Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Barclays PLC Has $271,000 Position in Organogenesis Holdings Inc. …

etfdailynews.com

$271000
OFF

Barclays PLC Increases Position In Zura Bio Limited (NASDAQ:ZURA)

2 weeks from now

Jan 6, 2025 · Barclays PLC Grows Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Barclays PLC Has $271,000 Position in Organogenesis Holdings Inc. …

etfdailynews.com

FAQs about Barclays PLC Grows Stock Position in Zentalis Pharmaceuticals, Inc ... Coupon?

Does Barclays PLC own zentalis pharmaceuticals?

Barclays PLC’s holdings in Zentalis Pharmaceuticals were worth $277,000 at the end of the most recent quarter. Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GSA Capital Partners LLP increased its holdings in Zentalis Pharmaceuticals by 138.5% in the 3rd quarter. ...

Did hedge funds buy zentalis pharmaceuticals?

Several hedge funds have recently bought and sold shares of the stock. Decheng Capital LLC raised its stake in shares of Zentalis Pharmaceuticals by 46.2% in the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after acquiring an additional 970,859 shares during the last quarter. ...

Should you buy zentalis pharmaceuticals (zentalis)?

Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $10.00. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. ...

How much does zentalis Pharmaceuticals stock cost?

Shares of Zentalis Pharmaceuticals stock opened at $3.24 on Monday. The firm has a market cap of $230.90 million, a P/E ratio of -1.30 and a beta of 1.84. Zentalis Pharmaceuticals, Inc. has a 12 month low of $2.66 and a 12 month high of $18.07. The stock’s fifty day moving average price is $3.33 and its 200-day moving average price is $3.50. ...

How much did zentalis pharmaceuticals raise in an IPO?

(ZNTL) raised $131 million in an IPO on Friday, April 3rd 2020. The company issued 7,700,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO. What is Zentalis Pharmaceuticals' stock symbol? ...

How much did zentalis pharmaceuticals (zntl) earn?

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.36. ...